Rishabh Gupta
Tracked across 1 events · 6 articles · First seen Apr 02, 2026 · Last active Jul 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted New Drug Application for oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. The CRL is…
Impact: As CEO, Rishabh Gupta expressed confidence in OLC's efficacy and safety, and optimism about resolving the manufacturing issue and resubmitting the NDA.
Jun 30, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Rishabh Gupta live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard